You are here

sitravantinib

Mirati's long wait for next lung cancer med ends in phase 3 failure

Fierce Biotech

Wed, 05/24/23 - 06:53 pm

Mirati Therapeutics

clinical trials

non small cell lung cancer

Amid Buyout Buzz, Mirati Pushes Phase III NSCLC Study to Final Analysis

BioSpace

Sun, 12/4/22 - 01:17 pm

Mirati Therapeutics

clinical trials

non-small cell lung cancer

Mirati's Sitravatinib Shows Promising Phase II Results in Urothelial Cancer Patients

BioSpace

Mon, 09/21/20 - 11:40 pm

Mirati Therapeutics

urothelial cancer

Mirati's sitravatinib in combination with nivolumab shows 37% response rate in urothelial cancer

Seeking Alpha

Fri, 09/18/20 - 10:45 am

Mirati Therapeutics

clinical trials

urothelial cancer